Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Jan;57(2):205-214.
doi: 10.1111/apt.17286. Epub 2022 Nov 14.

Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial

Affiliations
Randomized Controlled Trial

Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial

Yaara Zisman-Ilani et al. Aliment Pharmacol Ther. 2023 Jan.

Abstract

Background: Crohn's disease requires effective patient-clinician communication for successful illness and medication management. Shared decision making (SDM) has been suggested to improve communication around early intensive therapy. However, effective evidence-based SDM interventions for Crohn's disease are lacking, and the impact of SDM on Crohn's disease decision making and choice of therapy is unclear.

Aim: To test the impact of SDM on choice of therapy, quality of the decision and provider trust compared to standard Crohn's disease care.

Methods: We conducted a multi-site cluster randomised controlled trial in 14 diverse gastroenterology practices in the US.

Results: A total of 158 adult patients with Crohn's disease within 15 years of their diagnosis, with no prior Crohn's disease complications, and who were candidates to receive immunomodulators or biologics, participated in the study. Among these, 99 received the intervention and 59 received standard care. Demographics were similar between groups, although there were more women assigned to standard care, and a slightly shorter disease duration among those in the intervention group. Participants in the intervention group more frequently chose combination therapy (25% versus 5% control, p < 0.001), had a significantly lower decisional conflict (p < 0.05) and had greater trust in their provider (p < 0.05).

Conclusions: With rapidly expanding medication choices for Crohn's disease and slow uptake of early intensive therapy, SDM can personalise treatment strategies and has the potential to move the field of Crohn's disease management forward with an ultimate goal of consistently treating this disease early and intensively in appropriate patients.

Trial registration: Evaluating a Shared Decision Making Program for Crohn's Disease, ClinicalTrials.gov Identifier NCT02084290 https://clinicaltrials.gov/ct2/show/NCT02084290.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
CONSORT 2010 flow diagram
FIGURE 2
FIGURE 2
Proportion of patients selecting combination therapy
FIGURE 3
FIGURE 3
Trust in the doctor’s decisions about which medical treatments are best for you

Comment in

References

    1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389(10080):1741–55. 10.1016/S0140-6736(16)31711-1 - DOI - PubMed
    1. D’Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008;371(9613):660–7. 10.1016/S0140-6736(08)60304-9 - DOI - PubMed
    1. Siegel CA, Yang F, Eslava S, Cai Z. Treatment pathways leading to biologic therapies for ulcerative colitis and Crohn’s disease in the United States. Clin Transl Gastroenterol. 2020;11(2):e00128. 10.14309/ctg.0000000000000128 - DOI - PMC - PubMed
    1. Siegel CA, Refocusing IBD. Patient management: personalized, proactive, and patient-centered care. Am J Gastroenterol. 2018;113(10):1440–3. 10.1038/s41395-018-0246-x - DOI - PubMed
    1. Bewtra M, Reed SD, Johnson FR, Scott FI, Gilroy E, Sandler RS, et al. Variation among patients with Crohn’s disease in benefit vs risk preferences and remission time equivalents. Clin Gastroenterol Hepatol. 2020;18(2):406–414.e7. 10.1016/j.cgh.2019.05.010 - DOI - PubMed

Publication types

Associated data